Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo

NCT00655824 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00655824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00655824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
January 1, 2008
Completion date
March 19, 2013
Enrollment
124 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid